[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumonia-ventilator-associated\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumonia-ventilator-associated":286},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,69,95,121,161,191,214,237,258],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100448259","biomarkers-for-ventilator-associated-pneumonia-100448259",false,"NCT05117125","Biomarkers for Ventilator-associated Pneumonia","Biomarkers for Prediction of and Diagnosis of Ventilator-associated Pneumonia","VAPmarkers","Inclusion Criteria:\n\n* Admission to an intensive care unit\n* Intubation within last 24 hours\n* Anticipated mechanical ventilation of at least 48 hours\n\nExclusion Criteria:\n\n* FiO2 above 70% or PEEP above 15\n* Severe coagulopathy (spontaneous PK(INR) \\>1.8 or thrombocytes \\\u003C50). Prophylaxis treatment dose of LMWH or factor Xa inhibitors\u002FNOAC is not an exclusion criteria. If higher doses of these substances are administered, the responsible clinician should be consulted before sample collection.\n* Ongoing infection of the lungs at admission to the ICU.\n* Severely elevated or instable intracranial pressure.","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.",[25],"Pneumonia, Ventilator-Associated",[27],"VAP","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":32},"2021-10-15",{"date":36,"type":21},"2028-12-31",{"name":38,"class":39},"Region Skane","OTHER",5,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100619861","bis-in-icu-interventional-study-100619861","NCT07350122","BIS in ICU Interventional Study","Effect of BIS-Guided Sedation on Clinical Outcomes in Postoperative Cardiac Surgery ICU Patients: A Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing cardiac surgery with subsequent admission to the intensive care unit (e.g., valve surgery, coronary artery bypass grafting, aortic surgery)\n* Planned or expected duration of invasive mechanical ventilation \\> 6 hours postoperatively\n* Requirement for continuous sedation during ICU stay\n\nExclusion Criteria:\n\n* Pre-existing neurological disorders affecting consciousness or sedation assessment (e.g., severe dementia, epileptic encephalopathy).\n* Acute neurological events in the perioperative period (e.g., stroke, intracranial hemorrhage).\n* Severe hepatic dysfunction (Child-Pugh Class C).\n* Participation in another interventional study potentially affecting sedation or cognitive outcomes.\n* Pregnancy or lactation.\n* Do-not-intubate (DNI)\u002FDo-not-resuscitate (DNR) orders or documented limitation of therapy.\n* Patients in whom short-term survival is deemed unlikely due to the clinical course.",{"count":49,"type":21},144,"INTERVENTIONAL",[52],"NA","This study will test whether using a Bispectral Index (BIS) monitor to guide sedation can reduce the amount of sedative medication given to adults in the intensive care unit (ICU) after cardiac surgery. BIS is a non-invasive, EEG-based monitor that shows a number from 0-100 to reflect level of consciousness. Researchers will compare BIS-guided sedation to standard sedation guided by clinical scales (such as the Richmond Agitation-Sedation Scale, RASS).\n\nAbout 144 participants will be randomly assigned (1:1) to one of two groups at two hospitals in Austria (Medical University of Graz and Klinikum Wels-Grieskirchen). In the BIS group, clinicians will use BIS values and standard care to titrate sedation and will aim to avoid sustained BIS values below 50. In the control group, sedation will follow standard practices using clinical scales; BIS will be recorded but hidden from caregivers. The trial is open-label for treating staff; outcome assessors and data analysts will be blinded.\n\nParticipants will be in the study during their ICU sedation and mechanical ventilation period (typically more than 6 hours), with follow-up through ICU and hospital discharge. The primary outcome is the time-averaged dose of propofol (mg\u002Fkg\u002Fh) given during continuous ICU sedation until weaning (up to 72 hours). Secondary outcomes include duration of ventilation and sedation, depth of sedation measures, sedative and catecholamine doses, pulmonary infections (including ventilator-associated pneumonia), ICU and hospital length of stay, delirium, and in-hospital mortality.\n\nRisks are minimal and may include mild skin irritation from forehead electrodes. Possible benefits include improved sedation management; benefits are not guaranteed. Taking part is voluntary.",[55,56,57,58,25],"Cardiac Surgical Procedures (Postoperative Population)","Critical Illness","Postoperative Complications (Cardiopulmonary)","Delirium - Postoperative","NOT_YET_RECRUITING","2026-05-28",{"date":62,"type":32},"2026-05-29",{"date":64,"type":21},"2026-07",{"date":66,"type":21},"2027-06",{"name":68,"class":39},"Medical University of Graz",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":50,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100581261","tracheal-cuff-pressure-evaluation-study-100581261","NCT06848010","TRacheal Cuff PRessure Evaluation Study","TRAC-PRES","Inclusion Criteria:\n\n* Required invasive mechanical ventilation expected to last for more than 24h\n* Signed informed consent\n\nExclusion Criteria:\n\n* Intubated from more than 6 hours at the time of screening\n* Pregnancy\n* Previous surgery involving the airways",{"count":77,"type":21},54,[52],"Randomized clinical trial in mechanically ventilate critically ill patients. The study will evaluated the efficacy of a continous endotracheal tube (ETT) cuff pressure controller (TRACH FLUSH group) compared to manual monitoring and inflation (STANDARD group).\n\nPatients intubated, from at least 24 hours and with a predicted duration of invasive mechanical ventilation longer than 72 hours, will be randomized to the use of TRACH FLUSH versus nurse operated analogic cuff pressure controller q8.\n\nHypotesis of the study is the superiority of the continuous cuff pressure controller in maintaining cuff pressure within the target value, thus decreasing the incidence of microaspiration events.\n\nAim of the study are 1) to compare the incidence of cuff pressure value detection outside the target range between the TRACH FLUSH and the STANDARD group, and 2) to compare the incidence of sputum samples positive for (amylase and\u002For pepsin), a surrogate for tracheal micro-aspiration event.",[25,81],"Mechanical Ventilation",[83,84],"pressure cuff control","mechanical ventilation","2026-01-26",{"date":87,"type":32},"2026-01-28",{"date":89,"type":21},"2026-02-15",{"date":91,"type":21},"2027-12-31",{"name":93,"class":39},"Policlinico Hospital",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":94},"100606920","vap-incidence-and-adequation-to-srlf-2017-diagnostic-among-an-intensive-care-medicine-service-for-the-period-2022--2024-100606920","NCT07181824","VAP Incidence and Adequation to SRLF 2017 Diagnostic Among an Intensive Care Medicine Service for the Period 2022 à 2024","PAVM-RéaCHSF","Inclusion Criteria:\n\n* Adults ≥ 18 years\n* Hospitalization in Intensive care unit for the period between 01\u002F01\u002F2022 and 31\u002F12\u002F2024\n* Intubation and mechanical ventilation for \\> 48h\n* Positive respiratory sample\n\nExclusion Criteria:\n\n* Decision of therapeutic limitation\n* Organ donors\n* Patient refuse to participate",{"count":103,"type":21},100,"The goal of this observational study is to to analyze respiratory samples performed in mechanically ventilated ICU patients and to assess whether the SRLF criteria for defining VAP were respected among patients admited to the Intensive care medicine at a regional hospital en France",[106],"Pneumonia Ventilator Associated",[108,27,109,110,111],"Ventilatory associated pneumonia","Intensive Care medicine","Mechanical ventilation","Pneumonia","2025-12-08",{"date":114,"type":32},"2025-12-09",{"date":116,"type":32},"2025-08-25",{"date":118,"type":21},"2026-06-30",{"name":120,"class":39},"Centre Hospitalier Sud Francilien",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":133,"studyType":22,"phases":4,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":157,"locationsCount":160},"100611396","reduction-of-the-incidence-of-nav-in-neonatal-units-inbernav-neo-100611396","NCT07240038","Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)","Evaluation of an Evidence Based, Bundled Intervention to Reduce Incidence of Ventilator-associated Pneumonia in Neonatal Units (INBERNAV-Neo)","INBERNAV-Neo","Inclusion Criteria:\n\n* Patients admitted to participating NICUs who are in IMV for at least 48 hours, regardless of birth weight, gestational age or medical condition.\n\nExclusion Criteria:\n\n* Patients who remain in IMV less than 48 hours.\n* Decision of the healthcare professional in charge of the patient's treatment to exclude their participation at any moment due to the considerations of necessity.","0 Days","6 Months",{"count":132,"type":21},1500,"365 Days","The aim of this project is to achieve useful, universal and standardized definitions for the diagnosis and prevention of ventilator-associated neumonia in patients in the Neonatal Intensive Care Unit (NICU). To this end, a set of recommendations and best practice protocols have been developed in which the healthcare team of the participating units will be trained. These protocols will include evidence-based recommendations for daily practice (oral care, suctioning practices, patient positioning...) and guidelines for the diagnosis, with the goal of improving and standardizing the care that is currently carried out in each unit.\n\nTo evaluate the extent to which this intervention helps to reduce the frequency of ventilator-associated pneumonia and minimize its impact, a surveillance registry of the patient on invasive mechanical ventilation will be carried out. This registry consists of the collection of general data (sex, type of delivery, gestational age...), the drugs used during the registry (use or not of antibiotics) and the duration of the period during which the patient is under surveillance. If the patient develops pneumonia during the duration of intubation, the clinical and radiological (and in some cases microbiological) data necessary for its diagnosis and the treatment used will be collected.\n\nThe study is composed of several phases, but if we exclude the phases of formation and structure of the teams, literature review, resource preparation and data processing, the study is composed of 3 clearly differentiated phases in which patients are included. In the first phase, the coordinating team will only give the researchers of each hospital access to the forms and a brief explanation of how to fill them in, but instructing them to follow the usual diagnostic criteria. Once an established period of time has finished, the whole team belonging to the NICUs included in the project will be trained. Finally, after the training period, the teams will incorporate the preventive measures and diagnostic criteria seen in the training to their usual practice. To track behavioral changes from one phase to the next, the researchers will fill out forms to monitor the implementation of measures. Once this last phase has been completed, the results obtained will be analysed and the changes in prevention and diagnosis will be evaluated.",[106,136,137],"Pneumonia Neonatal","Healthcare-associated Infections",[139,140,141,142,143,144,145,146,147,148,149,150],"neonate","ventilator-associated pneumonia","quasi-experimental","multicenter","prevention","epidemiologic surveillance","clinical diagnosis","microbiological diagnostics","NICU","intervention","good clinical practice","patient safety","2025-11-19",{"date":153,"type":32},"2025-11-20",{"date":155,"type":32},"2024-04-26",{"date":118,"type":21},{"name":158,"class":159},"Biobizkaia Health Research Institute","OTHER_GOV",39,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":50,"phases":170,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":190},"100504092","phase-3-human-recombinant-interferon-gamma-in-the-treatment-of-ventilator-acquired-pneumonia-in-icu-patients-100504092","NCT05843786","Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients","IGNORANT","Inclusion Criteria:\n\n* adult patients hospitalized in intensive care unit\n* under mechanical ventilation for more than 5 days\n* having a first episode of VAP (with a Clinical Pulmonary Infectious Score (CPIS score) \\>6)\n* treated with antibiotics for less than 24 hours\n* with monocyte HLA-DR \\\u003C 8000 AB\u002FC\n* written informed consent signed by the patient's trusted support person, or in the absence of the patient's representative and taking into account the agreement of the relative obtained by telephone emergency certificate completed and signed by the investigator\n* membership of a social security scheme\n\nExclusion Criteria:\n\n* inability to administer the first dose of treatment in the study within 48 hours of the start of antibiotic therapy (antibiotic therapy for VAP)\n* Noradrenaline \\> 0.25 mcg\u002Fkg\u002Fmin\n* Immunosuppression, defined by:\n\n  * solid tumor with chemotherapy in the last 3 months\n  * progressive metastatic disease\n  * hematological disease\n  * solid organ transplantation\n  * HIV infection (AIDS stage or not)\n  * corticosteroid therapy at any dose for more than 3 months\n  * ≥ 1 mg\u002Fkg of Prednisone equivalent for more than 7 days\n  * immunosuppressive therapy\n* Head and\u002For cervical spine trauma : with a predictable impact on the duration of mechanical ventilation (left to the investigator's judgement), the investigator will assess whether the patient meets the following neurological criteria for extubation during their recovery:\n* A level of consciousness assessed as 0 or 1 on the Richmond Agitation-Sedation Scale (RASS)\n* FiO2 \\\u003C40%\n* PEEP level \\\u003C5 cmH2O\n* A FR\u002FVt ratio \\\u003C105\n* Effective cough\n* Response to simple commands\n* Administration of noradrenaline \\\u003C 0.2 mcg\u002Fkg\u002Fmin\n* Cardiocirculatory arrest\n* Burn patient\n* Cirrhosis with Child B or C score\n* Infection with Aspergillus spp.\n* Refusal to participate\n* Patient participating in another interventional research in progress or including an exclusion period still in progress at pre-inclusion (excluding interventional research of 2° not interfering with the endpoints of the study according to the judgment of the principal investigator)\n* Lack of social coverage\n* Patient under curatorship or guardianship\n* Pregnant or breastfeeding women\n* Patient admitted to intensive care for SARS-Cov2 pneumonia\n* Known allergy to latex\n* Hypersensitivity to the active substance (interferon gamma-1b) or known hypersensitivity to related products, such as another interferon, or to any of the following excipients: Mannitol, Disodium succinate hexahydrate, Succinic acid, polysorbate 20\n* Existence of chronic heart disease with FeVG\\\u003C45%\n* Major hepatic impairment (total bilirubin\\>60 mg\u002FL or 102 mcmol\u002FL, equivalent to 3 SOFA points)\n* thrombocytopenia \\\u003C50000\u002Fmm3 (equivalent to 3 SOFA points) AST and\u002For ALT \\> 5N Lipase \\> 3N Severe chronic renal failure (creatinine clearance MDRD\\\u003C 10 ml\u002Fmin\u002F1.73m2)\n* Thrombocytopenia \\\u003C50,000\u002Fmm3 (equivalent to 3 SOFA points)\n* Respiratory failure requiring home oxygen therapy\n* Persons under court protection",{"count":169,"type":21},132,[171],"PHASE3","Clinical presentation of patients after severe injury such as a severe infection, trauma or extensive burns is characterized by the simultaneous occurrence of dysregulation of the initial inflammatory response and immunosuppression associating quantitative and functional alterations of innate and adaptive immune cells. These acquired immune dysfunctions have been associated with an increased susceptibility to nosocomial infections, foremost among which are ventilator-associated pneumonia (VAP). Despite the implementation of a set of preventive measures, the incidence of these VAP remains high in intensive care, with rates in Europe of 1.5% per day of ventilation.\n\nPost-aggressive immunosuppression is characterized by the decrease in the expression of HLA-DR (belonging to the type II major histocompatibility complex, MHC-II) on the surface of monocytes (mHLA-DR). The administration of interferon gamma (IFNγ) can restore the level of mHLA-DR and may possibly improve the prognosis as an adjuvant therapy associated to antibiotics. However, the level of proof of this therapeutic strategy is low, limited to small cohorts of patients, or clinical studies without prior immunodepression assessment. The objective of this study is to conduct a randomized, double-blind, placebo-controlled superiority trial to assess the effect of IFNγ administration on the duration of mechanical ventilation following the first episode of VAP in patients having an HLA-DR \\\u003C 8000 AB\u002FC\n\nAll reported data about recombinant human IFNγ 1b for the control of secondary infections in patients with septic shock used the dose of 100 micrograms per day by subcutaneous route for 3 to 5 days . At this dose, no retrospective study has reported any serious adverse effects and recombinant human IFNγ 1b allows an increase in monocyte membrane expression of mHLA-DR.",[25],[56,175,176,177,178,179,180],"Interferon-gamma","Immunodepression","Sepsis","Trauma","Monocyte HLA-DR","immunostimulation","2025-11-18",{"date":183,"type":32},"2025-11-21",{"date":185,"type":32},"2023-06-30",{"date":187,"type":21},"2027-07-30",{"name":189,"class":39},"Hospices Civils de Lyon",9,{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":94},"100596986","antibiotic-treatment-for-pneumonia-caused-by-stenotrophomonas-maltophilia-in-icu-patients-100596986","NCT07052604","Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years)\n* Hospitalized in Medical Intensive Care Unit between January 1, 2018, and December 31, 2023\n* Intubated and mechanically ventilated\n* Diagnosed with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia\n\nExclusion Criteria:\n\n* Patients under 18 years old\n* Patients who refuse the use of their data for research purposes",{"count":198,"type":21},300,"This study looks at how different antibiotic treatments affect patients in intensive care who have pneumonia caused by the bacteria Stenotrophomonas maltophilia. It compares using one antibiotic versus two antibiotics, and treatment lengths of 7 days versus 14 days, to see which approach helps patients survive better. The study also examines how resistant the bacteria are to antibiotics and how often the pneumonia comes back.",[25,201,202,203,204],"Stenotrophomonas Maltophilia","Intensive Care Units","Anti-Bacterial Agents","Drug Resistance, Bacterial","2025-06-26",{"date":207,"type":32},"2025-07-04",{"date":209,"type":32},"2023-12-15",{"date":211,"type":21},"2025-09-15",{"name":213,"class":39},"Centre Hospitalier de Saint-Denis",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":223,"studyType":22,"phases":4,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":94},"100552036","predicting-ventilator-associated-lower-respiratory-tract-infection-outcomes-using-sequenced-based-early-microbiological-response-100552036","NCT06467864","Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response","Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response: A Multi-center Prospective Study","Inclusion Criteria:\n\n* Aged 18 years and above.\n* Previously relied on mechanical ventilation (endotracheal intubation or tracheotomy) for breathing assistance, and the duration of mechanical ventilation was more than 48h.\n* Lower respiratory tract infection based on at least two of the followings: abnormal temperature (body temperature greater than 38.5°C or less than 36.5°C), leucocyte count abnormality (leucocyte count greater than 12\\*10\\^9\u002FL or less than 4\\*10\\^9\u002FL), and the presence of purulent tracheal secretions.\n\nExclusion Criteria:\n\n* Bronchoscopy and respiratory specimen collection were not performed at screening (Day 1) and after 3 days of treatment (Day 4).\n* Refusal of patients or families to participate in the study\n* After initial screening, bronchoscopy was performed to obtain BALF for bacterial culture. The results of the culture showed no evidence of infection by study-associated lower respiratory pathogens.\n\nNote: The evidence of infection was defined as a single positive bacterial culture (pathogen quantification ≥10\\^4 cfu\u002Fml or \"++\" and more) on Day1. And the study-associated causative pathogens are Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Staphylococcus aureus. Additionally, the included patient must have single infection with one of these pathogens.",{"count":222,"type":21},200,"28 Days","We are using a tool called QtNGS (quantitative targeted amplicon-based next-generation sequencing ) to measure the abundance of local pathogens in patients with ventilator-associated lower respiratory tract infections. We hypothesize that changes in pathogen abundance before and after treatment are related to patient outcomes. This study aims to evaluate the effectiveness of the tool by analyzing the changes in pathogen abundance and exploring the relationship between these changes and clinical outcomes.",[25,226,227],"Respiratory Tract Infections","Prognosis","2025-05-22",{"date":230,"type":32},"2025-05-23",{"date":232,"type":32},"2024-04-01",{"date":234,"type":21},"2026-01-29",{"name":236,"class":39},"The First Affiliated Hospital with Nanjing Medical University",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":94},"100562737","immunity-markers-in-intensive-care-patients-and-ventilator-associated-pneumonia-100562737","NCT06607055","Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia","Monitoring of Immunity Markers in Intensive Care Patients and Link with Recurrence and Relapse of Ventilator-associated Pneumonia","IMMUNAIX","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient admitted in the Intensive Care Unit of the CHIAP\n* Patient under mechanical ventilation\n* Patient with infectious pneumonia\n* Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives\n* Patient beneficiary of French social security, whatever the regime\n\nExclusion Criteria:\n\n* Patient under 18 years old\n* Patient with severe neutropenia (neutrophils \\\u003C 0.5 G\u002FL)\n* Patient under immunosuppressive treatment\n* Use of corticosteroids (intravenous or oral) prior to ICU admission\n* Use of therapeutic antibodies\n* Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion\n* End of chemotherapy 6 months prior to inclusion\n* Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage)\n* Patients with a decision to limit or discontinue active therapies, at the time of inclusion\n* Patients with an estimated ICU stay of less than 48 hours\n* Participation in an interventional study\n* Patient deprived of their liberty\n* Patient under tutorship or curatorship\n* Pregnant or breastfeeding woman",{"count":246,"type":21},40,"The goal of this observational study is to show the direct correlation between the occurrence of recurrence of VAP and postagressive immunoparalysis, monitored by HLA-DR rate below litterature-acknowledged threshold, in a well conducted antibiotherapy context, in patient admitted in the Intensive Care Unit.\n\nThe main questions it aims to answer are:\n\n* evaluation of the association between death and persistence of immunoplegia using HLA-DR monitoring\n* search an association between immunoplegia depth and severity of the initial state of shock\n* search an association between immunoplegia depth and viral reactivation\n* compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence Blood samples will be taken from participants to HLA-DR dosage, at the time of inclusion and once a week then.",[25],"2024-09-18",{"date":251,"type":32},"2024-09-23",{"date":253,"type":32},"2023-10-04",{"date":255,"type":21},"2025-09",{"name":257,"class":39},"Centre Hospitalier Intercommunal Aix-Pertuis",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":50,"phases":267,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":94},"100326281","automated-oxygen-administration-in-patients-with-hypoxemic-pneumonia-and-pleuropneumonia-100326281","NCT03527992","Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia","OPPAÎ","Inclusion Criteria:\n\n* Adult\n* Patient living at home or in an institution\n* Patient hospitalized for less than 48 hours\n* Pneumonia defined (according to the 2006 French-speaking infectious pneumology society (SPILF) criteria) by:\n\n  * respiratory functional symptoms (cough, sputum, dyspnea, chest pain) and\n  * Hyperthermia \\>38,5°C or hypothermia \\\u003C36°C and\n  * Radiological Signs of Pneumonia\n* Hypoxia : SpO2 \\\u003C 94% in ambient air and\u002For PaO2\\\u003C 60 mmHg in ambient air\n\nExclusion Criteria:\n\n* Pneumonia acquired at the hospital.\n* Patient hospitalized in another department more than 48 hours before admission\n* Chronic respiratory failure\n* Active neoplasia\n* Patients undergoing oxygen therapy and \u002F or long-term NIV\n* Associated cardiac decompensation (clinical signs and \u002F or NTproBNP\\> 1800ng \u002F mL) (3\n* Initial Need for high flow oxygen therapy or ventilatory support (NIV, VI)\n* Difficulties expected from home support.",{"count":266,"type":21},128,[52],"Hypoxemic pneumonia is a major cause of hospitalization in Pulmonology. The patient's dependency on oxygen prevents early discharge from the hospital. An automated oxygen therapy is a system that allows administration of oxygen with a flow that is automatically adjusted to the patient's saturation, which is continuously monitored. This system has proven to be particularly effective with chronic obstructive pulmonary disease (COPD) patients, by decreasing the time spent in hypoxia and hyperoxia, and by accelerating the weaning of oxygen. Our hypothesis is that automated oxygen therapy leads to a diminution on the length of hospital stay.",[111,25,270],"Length of Stay",[272,273,274,275,276],"Randomized Therapeutic trial","Hypoxemic pneumonia","Automated oxygen therapy","Length of stay","medico-economic cost","2024-08-01",{"date":279,"type":32},"2024-08-02",{"date":281,"type":32},"2018-03-09",{"date":283,"type":21},"2028-10",{"name":285,"class":39},"University Hospital, Toulouse","Pneumonia, Ventilator Associated"]